Citations

Clear

8 citation(s) found for "Lim, Do Young".

Current Knowledge and Gaps in Geriatric Rehabilitation among Physical and Rehabilitation Medicine specialists
Capodaglio, Paolo , Antoniadou, Eleftheria , Oh‐Park, Mooyeon , Frontera, Walter R, Terzic, Carmen M., Ambrose, Anne Felicia , Pola, Marta Supervía, Kutsal, Yesim Gokce, Strasser, Dale C., Bean, Jonathan F. , Seijas, Vanessa , Lim, Jae-Young, Frontera, Walter R. , Han, Der‐Sheng , Gimigliano, Francesca , Kutsal, Yeşim Gökçe, Nguyen, Vu Q. C.

Mayo Clinic

Annals of Geriatric Medicine and Research | August 12, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.4235/agmr.26.0149 | PMID 42581575 Get It

CDCP1 Deletion Protects Against Pressure Overload-Induced Cardiac Dysfunction and Fibrosis in Mice
Pereira, Naveen, Ghazal, Rachad, wang, Min, Cao, Jenny Jia Ling, Wang, Li , Sherman, William , John, August, Vyas, Hridyanshu , Roos, Carolyn, Huang, Runqing, Ördög, Tamás , Trussoni, Christy, Lim, Do Young , Sinagra, Gianfranco, Weinshilboum, Richard M. , Liu, Duan , Lambert, Laura , Miller, Jordan , Tschumperlin, Daniel, Srinivas, Akshatha N. , Sherman, Will A , Ordog, Tamas , Wang, Chen , Baker, Darren J , Weinshilboum, Richard M. , Liu, Duan , Lambert, Laura J, Pereira, Naveen, Ghazal, Rachad , Cao, Jenny Jia Ling , Wang, Li, Marín-Goñi, Irene , Wang, Chen , Trussoni, Christy E. , Baker, Darren J. , Sinagra, Gianfranco , Tschumperlin, Daniel J.

Mayo Clinic

No container title available | May 8, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-9236741/v1 | PMID 42147194 Get It

Abstract Human genomic studies link reduced CUB domain-containing protein 1 (CDCP1) expression with myocardial recovery in heart failure. While CDCP1 regulates cardiac fibroblast proliferation in vitro, it’s in vivo role in cardiac fibrosis remains unclear. Using a Cdcp1 -knockout (KO) angiotensin II/phenylephrine mouse model, we show that Cdcp1 deletion reduces echocardiographic left ventricular mass, histologic cardiac fibrosis, and pro-fibrotic gene expression, along with decreased fibroblast activation and inflammatory markers. Spatial transcriptomics identified a pressure overload–expanded fibroblast subpopulation enriched for growth factor and TGF-β signaling (FB5), which was markedly attenuated in Cdcp1 -KO hearts, alongside reduction of a pro-inflammatory cardiomyocyte subtype (CM4). Complementary studies in human ventricular fibroblasts demonstrate that CDCP1 knockdown reduced extracellular matrix gene expression and collagen I deposition. These findings establish CDCP1 as a regulator of cardiac fibrotic remodeling in vivo and open avenues for its further investigation as a potential therapeutic target.
Evaluation of [18F]F-CNBI and [18F]F-CNPI PET Probes in GSK-3β Transgenic Mice
Kethamreddy, Manasa, Gundam, Surendra Reddy, Rivera, Alexander, Bansal, Aditya , Lim, Do Young , Giri, Sharmila, Larson, Nicholas B. , Lowe, Val J. , Pandey, Mukesh K. , Rivera, Andy González, Pandey, Mukesh K , Larson, Nicholas B , Wootla, Bharath , Baker, Darren J.

Mayo Clinic

ACS Chemical Neuroscience | August 15, 2025 | Volume: 16 | Issue: 17 | Pages: 3340-3353

10.1021/acschemneuro.5c00442 | PMID 40815164 Get It

Introducing W. Ray Kim, MD, our 2024 AASLD president
Lim, Young‐Suk , Kwong, Allison J. , Allen, Alina M. , Allen, Alina M , Kwong, Allison

Mayo Clinic

Hepatology | October 31, 2023 | Volume: 79 | Issue: 1 | Pages: 21-24

10.1097/hep.0000000000000650 | PMID 38099648 Get It

Evidence for Benefits of Early Treatment Initiation for Chronic Hepatitis B
Lim, Young‐Suk , Kim, W. Ray , Dieterich, Douglas T. , Kao, Jia‐Horng , Flaherty, John F. , Yee, Leland J. , Roberts, Lewis R. , Razavi, Homie , Kennedy, Patrick , Kennedy, Patrick T F , Roberts, Lewis R

Mayo Clinic

Viruses | April 19, 2023 | Volume: 15 | Issue: 4 | Pages: 997

10.3390/v15040997 | PMID 37112976 Get It

Chronic hepatitis B (CHB) is the most common cause of hepatocellular carcinoma (HCC) worldwide. Antiviral treatment reduces the risk of HCC and mortality; nonetheless, globally in 2019, only 2.2% of CHB patients received treatment. Current international CHB guidelines recommend antiviral treatment only in subsets of patients with clear evidence of liver damage. This contrasts with hepatitis C or HIV where early treatment is recommended in all infected patients, regardless of end-organ damage. This narrative review aims to provide an overview of data on the early initiation of antiviral treatment and its related potential economic impact. Literature searches were performed using PubMed and abstracts from international liver congresses (2019–2021). Data on risk of disease progression and HCC and the impact of antiviral treatment in currently ineligible patients were summarized. Cost-effectiveness data on early antiviral treatment initiation were also collated. Accumulating molecular, clinical, and economic data suggest that early initiation of antiviral treatment could save many lives through HCC prevention in a highly cost-effective manner. In light of these data, we consider several alternative expanded treatment strategies that might further a simplified ‘treatment as prevention’ approach.
p21 produces a bioactive secretome that places stressed cells under immunosurveillance
Sturmlechner, Ines , Sine, Chance , Deursen, Erik-Jan van, Jeganathan, Karthik B. , Hamada, Naomi, Grašič, Jan , Friedman, David J. , Stutchman, Jeremy, Can, İsmail , Hamada, Masakazu , Lim, Do Young , Lee, Jeong‐Heon , Ördög, Tamás , Laberge, Rémi-Martin , Baker, Darren J. , Deursen, Jan M. van , Sine, Chance C, van Deursen, Erik-Jan, Jeganathan, Karthik B , Friedman, David , Stutchman, Jeremy T, Can, Ismail , Lim, Do Young , Lee, Jeong-Heon , Ordog, Tamas , Shapiro, Virginia S , Baker, Darren J , Li, Hu , van Deursen, Jan M , Sturmlechner, Ines , Zhang, Cheng , Hamada, Masakazu, Shapiro, Virginia Smith

Mayo Clinic

Science | October 28, 2021 | Volume: 374 | Issue: 6567 | Pages: No page available

10.1126/science.abb3420 | PMID 34709885 Get It

The clock is ticking for senescent cells Senescent cells promote their own recognition and removal through the immune system by generating a bioactive secretome called the senescence-associated secretory phenotype (SASP). Sturmlechner et al . report that the cell cycle regulator p21 directs an early form of the SASP, which they call the p21-activated secretory phenotype (PASP) (see the Perspective by Reen and Gil). As part of the PASP, the chemokine CXCL14 attracts macrophages, which monitor stressed cells expressing elevated p21. If stressed cells recuperate and p21 levels return to normal within 4 days, then macrophages disengage from their targets. Otherwise, macrophages recruit cytotoxic T cells that facilitate target cell removal. Other cell cycle regulators such as p16 can induce many factors overlapping with the PASP, but p21 uniquely drives this CXCL14-mediated “timer” mechanism of senescent cell immunosurveillance. —STS
ARC Is a Critical Protector against Inflammatory Bowel Disease (IBD) and IBD-Associated Colorectal Tumorigenesis
Wang, Qiushi , Chang, Xiaoyu , Lim, Do Young , Wang, Keke , Bai, Ruihua , Wang, Ting , Ryu, Joohyun , Chen, Hanyong, Yao, Ke , Ma, Wei-Ya, Bode, Ann M. , Boardman, Lisa , Zhang, Tianshun , Ryu, Joohyun , Boardman, Lisa A. , Dong, Zigang

Mayo Clinic

Cancer Research | August 19, 2020 | Volume: 80 | Issue: 19 | Pages: 4158-4171

10.1158/0008-5472.can-20-0469 | PMID 32816906 Get It

Abstract The key functional molecules involved in inflammatory bowel disease (IBD) and IBD-induced colorectal tumorigenesis remain unclear. In this study, we found that the apoptosis repressor with caspase recruitment domain (ARC) protein plays critical roles in IBD. ARC-deficient mice exhibited substantially higher susceptibility to dextran sulfate sodium (DSS)-induced IBD compared with wild-type mice. The inflammatory burden induced in ARC-deficient conditions was inversely correlated with CCL5 and CXCL5 levels in immune cells, especially CD4-positive T cells. Pathologically, ARC expression in immune cells was significantly decreased in clinical biopsy specimens from patients with IBD compared with normal subjects. In addition, ARC levels inversely correlated with CCL5 and CXCL5 levels in human biopsy specimens. ARC interacted with TNF receptor associated factor (TRAF) 6, regulating ubiquitination of TRAF6, which was associated with NF-κB signaling. Importantly, we identified a novel ubiquitination site at lysine 461, which was critical in the function of ARC in IBD. ARC played a critical role in IBD and IBD-associated colon cancer in a bone marrow transplantation model and azoxymethane/DSS-induced colitis cancer mouse models. Overall, these findings reveal that ARC is critically involved in the maintenance of intestinal homeostasis and protection against IBD through its ubiquitination of TRAF6 and subsequent modulation of NF-κB activation in T cells. Significance: This study uncovers a crucial role of ARC in the immune system and IBD, giving rise to a novel strategy for IBD and IBD-associated colon cancer therapy.
Anti‐viral therapy is associated with improved survival but is underutilised in patients with hepatitis B virus‐related hepatocellular carcinoma: real‐world east and west experience
Chen, Vincent , Yeh, Ming-Lun, Le, An K. , Jun, Mi Jung, Saeed, Waqar Khalid , Yang, Ju Dong , Huang, Chung‐Feng , Lee, H. Y., Tsai, Pei‐Chien , Giama, Nasra H., Kim, N. G., Nguyen, Phuong , Dang, Hansen , Ali, Hamdi A. , Zhang, N., Chuang, Wan‐Long , Roberts, Lewis R. , Yu, Ming‐Lung , Nguyen, Mindie H. , Chen, V L , Huang, C-F , Jun, D W , Yu, M-L , Nguyen, Mindie H , Roberts, Lewis R , Yeh, Ming-Lun , Yang, Ju Dong , Lee, M.‐H., Huang, Jee‐Fu , Dai, Chia-Yen , Lim, Young‐Suk

Mayo Clinic

Alimentary Pharmacology & Therapeutics | May 24, 2018 | Volume: 48 | Issue: 1 | Pages: 44-54

10.1111/apt.14801 | PMID 29797518 Get It

SummaryBackgroundHepatitis B virus (HBV) is the leading cause of hepatocellular carcinoma (HCC) worldwide. It remains incompletely understood in the real world how anti‐viral therapy affects survival after HCC diagnosis.MethodsThis was an international multicentre cohort study of 2518 HBV‐related HCC cases diagnosed between 2000 and 2015. Cox proportional hazards models were utilised to estimate hazard ratios (HR) with 95% (CI) for anti‐viral therapy and cirrhosis on patients' risk of death.ResultsApproximately, 48% of patients received anti‐viral therapy at any time, but only 17% were on therapy at HCC diagnosis (38% at US centres, 11% at Asian centres). Anti‐viral therapy would have been indicated for >60% of the patients not on anti‐viral therapy based on American criteria. Patients with cirrhosis had lower 5‐year survival (34% vs 46%; P < 0.001) while patients receiving anti‐viral therapy had increased 5‐year survival compared to untreated patients (42% vs 25% with cirrhosis and 58% vs 36% without cirrhosis; P < 0.001 for both). Similar findings were seen for other patient subgroups by cancer stages and cancer treatment types. Anti‐viral therapy was associated with a decrease in risk of death, whether started before or after HCC diagnosis (adjusted HR 0.62 and 0.79, respectively; P < 0.001).ConclusionsAnti‐viral therapy improved overall survival in patients with HBV‐related HCC across cancer stages and treatment types but was underutilised at both US and Asia centres. Expanded use of anti‐viral therapy in HBV‐related HCC and better linkage‐to‐care for HBV patients are needed.